


1 **Supplementary data**

2



3


4 **Figure S1: RodA-mRFP fusion complements $\Delta rodA$.** Phase images of $\Delta rodA$ +
5 empty vector, $\Delta rodA$ + *rodA-mRFP*, wildtype + empty vector, and wildtype + *rodA-mRFP*
6 were acquired and cell lengths were quantified using Oufiti, MATLAB (1), and visualized
7 using R Studio (58<n<204). Significance determined using analysis of variance
8 (ANOVA) followed by a Tukey post hoc test to conduct pairwise comparisons. ns, not
9 significant; *, p<0.05; **, p<0.01; ***, p<0.005.

10

11

12

13



14

15 **Figure S2: RodA-mRFP fusion localizes to the plasma membrane with**


16 **minimal degradation.** Lysates from *M. smegmatis* +/- *rodA-mRFP* were

17 separated into cytoplasmic (cyt) and membrane (mem) fractions by

18 ultracentrifugation and immunoblotted with anti-RFP antibodies. Protein

19 concentration normalized.

20




21

22 **Figure S3: Polarity of cell wall synthesis detected with TAMRA.** Polarity ratio of cell
 23 wall labeling (bright pole signal/total cell fluorescence) in wildtype and $\Delta rodA$ +/-
 24 mutanolysin/lysozyme. Nascent peptidoglycan labeled as in Fig. 2a except that click
 25 chemistry detection was with picolyl azide-TAMRA.

26

27



28

29 **Figure S4: Mutanolysin/lysozyme treatment leads to cell-wide damage.** (a)

30 Muramidases mutanolysin and lysozyme break the linkages between neighbouring
 31 glycans *N*-acetylglucosamine and *N*-acetylmuramic acid in the peptidoglycan backbone

32 (b) Phase contrast images of wildtype or $\Delta rodA$ *M. smegmatis* +/-


33 mutanolysin/lysozyme. Scale bars = 5 μ m. (c) *M. smegmatis* was labeled with 1 μ M

34 RADA, a D-amino acid mono-peptide that we previously showed incorporates into


35 peptidoglycan via L,D-transpeptidases (2) and coats the cell wall evenly after overnight

36 incubation with a low concentration (3). After washing, the culture was treated with

37 mutanolysin/lysozyme and loss of fluorescence along the length of the cells was
38 quantitated. As expected, after 2 hours labeling loss was observed at the poles in
39 untreated cells. Loss of fluorescence at the poles of lysozyme/mutanolysin-treated *M.*
40 *smegmatis* was not as pronounced, consistent with its slow growth in the presence of
41 the enzymes (Figure 5a). At this time point, sidewall loss of fluorescence was greatly
42 enhanced with enzyme treatment. Although mycobacterial growth precludes
43 interpretation of cell wall loss at the poles, these data suggest that
44 lysozyme/mutanolysin-mediated cell wall loss occurs along the *M. smegmatis* sidewall.
45 Signal not normalized. 58<n<102.



46
47 **Figure S5: RodA-mRFP and PonA1-mRFP location in cells treated with**
48 **lysozyme/mutanolysin.** Representative images of (a) RodA-mRFP and (b) PonA1-
49 mRFP imaged following mutanolysin/lysozyme treatment. Compare to Figure 1a. Scale
50 bars = 5 μm .




51

52 **Figure S6: RodA relocation is not observed in live cells.** Staining with dead stain
 53 SYTOX green reveals that there are no viable cells that display RodA-mRFP polar
 54 relocation phenotype associated with mutanolysin/lysozyme treatment. Because of
 55 spectral crossover of SYTOX Green into the RFP channel in combination with low
 56 signal intensity from RodA-mRFP, we were not able to capture RodA-mRFP signal in
 57 SYTOX Green-positive cells. Scale bars = 5 μ m.

58

59

60



61

62 **Figure S7: RodA is not required for growth in *M. smegmatis*.**

63

64

65

66 **Table S1: Primers used for fluorescent fusion constructs.**

67

gene of interest	primers for <i>M. smegmatis</i> gene
<i>rodA-mRFP</i>	TTAATTAAGAAGGAGATATACATatgatgacgacgcaaccccag
	gaCGTCCTCGGAGGAGGCcgagccgcctaccttttcgatcacctcgg
<i>lcp1-mRFP</i>	GCTTAATTAAGAAGGAGATATACATatgttgatcaggtccattgctgtg
	CGTCCTCGGAGGAGGCcgagccgccgttcacgcactgcgggtcgttgg
<i>fbpC</i> (MSMEG_3580) <i>-mRFP</i>	CTTAATTAAGAAGGAGATATACATatgcgcgccattgcagcatggaaag
	GTCCTCGGAGGAGGCcgagccgcccgtggcggactgagcgccgagcacc

<i>fbpC</i> (MSMEG_3580)	CTTAATTAAGAAGGAGATATACATatgagacgtgggttgagtctggttc
-mRFP	CGTCCTCGGAGGAGGCcgagccgcccttgatggtggcgaccagctcacc
	mRFP primers
<i>rodA-mRFP</i>	gatcgaaaaggtaggcggctcgGCCTCCTCCGAGGACGtcatca
	CCCAATTAATTAGCTAAAGCTTtcaGGCGCCGGTGGAGTGgc
<i>lcp1-mRFP</i>	gatgaCGTCCTCGGAGGAGGCcgagccgccgttacgcactgcgggtcg
	CCCAATTAATTAGCTAAAGCTTtcaGGCGCCGGTGGAGTGgcggc
	cctc
<i>fbpC</i> (MSMEG_3580)	gatgaCGTCCTCGGAGGAGGCcgagccgccgtggcgactgagcgccg
	CCCAATTAATTAGCTAAAGCTTtcaGGCGCCGGTGGAGTGgcggc
-mRFP	cctc
<i>fbpC</i> (MSMEG_3580)	gatgaCGTCCTCGGAGGAGGCcgagccgcccttgatggtggcgaccagc
	CCCAATTAATTAGCTAAAGCTTtcaGGCGCCGGTGGAGTGgcggc
-mRFP	cctc

68

69

70 References

- 71 1. Paintdakhi A, Parry B, Campos M, Irnov I, Elf J, Surovtsev I, Jacobs-Wagner C. 2016. Oufiti:
72 an integrated software package for high-accuracy, high-throughput quantitative microscopy
73 analysis. *Mol Microbiol* 99:767-77.
74
- 75 2. Garcia-Heredia A, Pohane AA, Melzer ES, Carr CR, Fiolek TJ, Rundell SR, Lim HC,
76 Wagner JC, Morita YS, Swarts BM, Siegrist MS. 2018. Peptidoglycan precursor synthesis
77 along the sidewall of pole-growing mycobacteria. *Elife* 7.

78 3. Melzer ES, Sein CE, Chambers JJ, Sloan Siegrist M. 2018. DivIVA concentrates
79 mycobacterial cell envelope assembly for initiation and stabilization of polar growth.
80 Cytoskeleton (Hoboken) 75:498-507.
81

82

83

84

85

86